2型糖尿病患者不同给药间隔服用格列美脲疗效的Meta分析  

Comparison of different dosing interval administration of glimepiride with same total dosage in type 2 diabetes mellitus: a meta-analysis

作　　者：刘洁 朱立勤[2] 陈凡[2] 魏晓晨[2] 

机构地区：[1]乌鲁木齐市第一人民医院,乌鲁木齐830002 [2]天津市第一中心医院,天津300192

出　　处：《实用药物与临床》2013年第10期926-928,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的评价2型糖尿病患者1次顿服与分2次服用格列美脲的疗效。方法利用RevMan 5.0软件对1994年至2012年1月国内外医学期刊发表的2型糖尿病患者1次/d顿服与分2次服用格列美脲疗效比较的随机对照试验进行Meta分析。结果采用固定效应模型,空腹血糖:Z=3.59,WMD=-0.51(-0.79,-0.23),P<0.05;早餐后2 h血糖:Z=2.00,WMD=0.40(0.01,0.78),P<0.05;糖化血红蛋白:Z=2.66,WMD=0.18(0.05,0.31),P<0.05;未见严重不良反应的报道。结论不同给药间隔口服格列美脲对空腹血糖、餐后血糖、糖化血红蛋白的控制程度有差别,控制空腹血糖2次/d疗效好,控制早餐后2 h血糖和糖化血红蛋白1次顿服疗效好。仍然需要大规模的多中心随机对照试验提供更科学的证据。Objective To evaluate once daily and twice daily administration of glimepiride with same total dosage in type 2 diabetes mellitus. Methods The once daily and twice daily administration of glimepiride with same total dosage in type 2 diabetes mellitus on randomized clinical trials published from 1994 to 2012 at home and abroad was evaluated by recta-analysis with RevMan 5.0. Results The fixed effects model was used to analyze, FPG ： Z = 3.59,WMD =-0. 51（ -0. 79, -0. 23） ,P 〈0. 05;PBG：Z = 2.00,WMD = 0. 40（0. 01,0. 78） ,P 〈0. 05;HbA1c：Z = 2. 66, WMD = 0. 18 （ 0.05,0. 31 ）, P 〈 0. 05. No serious adverse event was reported. Condusion There are differences in FPG, PBG and HbAlc between the different dosing interval of oral glimepiride; twice daily administration of glimepiride is more effective to reduce FPG, once daily administration of glimepiride is more effective to reduce PBG and HbAlc. Large-scale multicenter randomized clinical trials are still required to provide more scientific evidence.

关 键 词：格列美脲 给药间隔 META分析 

分 类 号：R587.1[医药卫生—内分泌]